1
|
Kurzawa-Akanbi M, Tzoumas N, Corral-Serrano JC, Guarascio R, Steel DH, Cheetham ME, Armstrong L, Lako M. Pluripotent stem cell-derived models of retinal disease: Elucidating pathogenesis, evaluating novel treatments, and estimating toxicity. Prog Retin Eye Res 2024; 100:101248. [PMID: 38369182 DOI: 10.1016/j.preteyeres.2024.101248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2023] [Revised: 02/13/2024] [Accepted: 02/14/2024] [Indexed: 02/20/2024]
Abstract
Blindness poses a growing global challenge, with approximately 26% of cases attributed to degenerative retinal diseases. While gene therapy, optogenetic tools, photosensitive switches, and retinal prostheses offer hope for vision restoration, these high-cost therapies will benefit few patients. Understanding retinal diseases is therefore key to advance effective treatments, requiring in vitro models replicating pathology and allowing quantitative assessments for drug discovery. Pluripotent stem cells (PSCs) provide a unique solution given their limitless supply and ability to differentiate into light-responsive retinal tissues encompassing all cell types. This review focuses on the history and current state of photoreceptor and retinal pigment epithelium (RPE) cell generation from PSCs. We explore the applications of this technology in disease modelling, experimental therapy testing, biomarker identification, and toxicity studies. We consider challenges in scalability, standardisation, and reproducibility, and stress the importance of incorporating vasculature and immune cells into retinal organoids. We advocate for high-throughput automation in data acquisition and analyses and underscore the value of advanced micro-physiological systems that fully capture the interactions between the neural retina, RPE, and choriocapillaris.
Collapse
|
2
|
Abraham N, Kolipaka T, Pandey G, Negi M, Srinivasarao DA, Srivastava S. Revolutionizing pancreatic islet organoid transplants: Improving engraftment and exploring future frontiers. Life Sci 2024; 343:122545. [PMID: 38458556 DOI: 10.1016/j.lfs.2024.122545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2023] [Revised: 02/16/2024] [Accepted: 03/04/2024] [Indexed: 03/10/2024]
Abstract
Type-1 Diabetes Mellitus (T1DM) manifests due to pancreatic beta cell destruction, causing insulin deficiency and hyperglycaemia. Current therapies are inadequate for brittle diabetics, necessitating pancreatic islet transplants, which however, introduces its own set of challenges such as paucity of donors, rigorous immunosuppression and autoimmune rejection. Organoid technology represents a significant stride in the field of regenerative medicine and bypasses donor-based approaches. Hence this article focuses on strategies enhancing the in vivo engraftment of islet organoids (IOs), namely vascularization, encapsulation, immune evasion, alternative extra-hepatic transplant sites and 3D bioprinting. Hypoxia-induced necrosis and delayed revascularization attenuate organoid viability and functional capacity, alleviated by the integration of diverse cell types e.g., human amniotic epithelial cells (hAECs) and human umbilical vein endothelial cells (HUVECs) to boost vascularization. Encapsulation with biocompatible materials and genetic modifications counters immune damage, while extra-hepatic sites avoid surgical complications and immediate blood-mediated inflammatory reactions (IBMIR). Customizable 3D bioprinting may help augment the viability and functionality of IOs. While the clinical translation of IOs faces hurdles, preliminary results show promise. This article underscores the importance of addressing challenges in IO transplantation to advance their use in treating type 1 diabetes effectively.
Collapse
Affiliation(s)
- Noella Abraham
- Pharmaceutical Innovation and Translational Research Lab (PITRL), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India
| | - Tejaswini Kolipaka
- Pharmaceutical Innovation and Translational Research Lab (PITRL), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India
| | - Giriraj Pandey
- Pharmaceutical Innovation and Translational Research Lab (PITRL), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India
| | - Mansi Negi
- Pharmaceutical Innovation and Translational Research Lab (PITRL), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India
| | - Dadi A Srinivasarao
- Pharmaceutical Innovation and Translational Research Lab (PITRL), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India
| | - Saurabh Srivastava
- Pharmaceutical Innovation and Translational Research Lab (PITRL), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, India.
| |
Collapse
|
3
|
Minne M, Terrie L, Wüst R, Hasevoets S, Vanden Kerchove K, Nimako K, Lambrichts I, Thorrez L, Declercq H. Generating human skeletal myoblast spheroids for vascular myogenic tissue engineering. Biofabrication 2024; 16:025035. [PMID: 38437715 DOI: 10.1088/1758-5090/ad2fd5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2023] [Accepted: 03/04/2024] [Indexed: 03/06/2024]
Abstract
Engineered myogenic microtissues derived from human skeletal myoblasts offer unique opportunities for varying skeletal muscle tissue engineering applications, such asin vitrodrug-testing and disease modelling. However, more complex models require the incorporation of vascular structures, which remains to be challenging. In this study, myogenic spheroids were generated using a high-throughput, non-adhesive micropatterned surface. Since monoculture spheroids containing human skeletal myoblasts were unable to remain their integrity, co-culture spheroids combining human skeletal myoblasts and human adipose-derived stem cells were created. When using the optimal ratio, uniform and viable spheroids with enhanced myogenic properties were achieved. Applying a pre-vascularization strategy, through addition of endothelial cells, resulted in the formation of spheroids containing capillary-like networks, lumina and collagen in the extracellular matrix, whilst retaining myogenicity. Moreover, sprouting of endothelial cells from the spheroids when encapsulated in fibrin was allowed. The possibility of spheroids, from different maturation stages, to assemble into a more large construct was proven by doublet fusion experiments. The relevance of using three-dimensional microtissues with tissue-specific microarchitecture and increased complexity, together with the high-throughput generation approach, makes the generated spheroids a suitable tool forin vitrodrug-testing and human disease modeling.
Collapse
Affiliation(s)
- Mendy Minne
- Tissue Engineering Lab, Department of Development and Regeneration, KU Leuven campus KULAK, Kortrijk, Belgium
| | - Lisanne Terrie
- Tissue Engineering Lab, Department of Development and Regeneration, KU Leuven campus KULAK, Kortrijk, Belgium
| | - Rebecca Wüst
- Tissue Engineering Lab, Department of Development and Regeneration, KU Leuven campus KULAK, Kortrijk, Belgium
| | - Steffie Hasevoets
- Biomedical Research Institute (BIOMED), Faculty of Medicine and Life Sciences, UHasselt, Diepenbeek, Belgium
| | - Kato Vanden Kerchove
- Tissue Engineering Lab, Department of Development and Regeneration, KU Leuven campus KULAK, Kortrijk, Belgium
| | - Kakra Nimako
- Tissue Engineering Lab, Department of Development and Regeneration, KU Leuven campus KULAK, Kortrijk, Belgium
| | - Ivo Lambrichts
- Biomedical Research Institute (BIOMED), Faculty of Medicine and Life Sciences, UHasselt, Diepenbeek, Belgium
| | - Lieven Thorrez
- Tissue Engineering Lab, Department of Development and Regeneration, KU Leuven campus KULAK, Kortrijk, Belgium
| | - Heidi Declercq
- Tissue Engineering Lab, Department of Development and Regeneration, KU Leuven campus KULAK, Kortrijk, Belgium
| |
Collapse
|
4
|
Baek A, Kwon IH, Lee DH, Choi WH, Lee SW, Yoo J, Heo MB, Lee TG. Novel Organoid Culture System for Improved Safety Assessment of Nanomaterials. NANO LETTERS 2024; 24:805-813. [PMID: 38213286 PMCID: PMC10811694 DOI: 10.1021/acs.nanolett.3c02939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/04/2023] [Revised: 12/24/2023] [Accepted: 01/03/2024] [Indexed: 01/13/2024]
Abstract
Over the past few decades, the increased application of nanomaterials has raised questions regarding their safety and possible toxic effects. Organoids have been suggested as promising tools, offering efficient assays for nanomaterial-induced toxicity evaluation. However, organoid systems have some limitations, such as size heterogeneity and poor penetration of nanoparticles because of the extracellular matrix, which is necessary for organoid culture. Here, we developed a novel system for the improved safety assessment of nanomaterials by establishing a 3D floating organoid paradigm. In addition to overcoming the limitations of two-dimensional systems including the lack of in vitro-in vivo cross-talk, our method provides multiple benefits as compared with conventional organoid systems that rely on an extracellular matrix for culture. Organoids cultured using our method exhibited relatively uniform sizing and structural integrity and were more conducive to the internalization of nanoparticles. Our floating culture system will accelerate the research and development of safe nanomaterials.
Collapse
Affiliation(s)
- Ahruem Baek
- Nano-Safety
Team, Safety Measurement Institute, Korea
Research Institute of Standards and Science (KRISS), Daejeon 34113, Republic of Korea
| | - Ik Hwan Kwon
- Bioimaging
Team, Safety Measurement Institute, Korea
Research Institute of Standards and Science (KRISS), Daejeon 34113, Republic of Korea
| | - Da-Hye Lee
- Biomolecular
Measurement Team, Bio-Metrology Group, Korea
Research Institute of Standards and Science (KRISS), Daejeon 34113, Republic of Korea
| | - Woo Hee Choi
- Department
of Microbiology, CHA University School of
Medicine, Seongnam 13488, Republic
of Korea
- Organoidsciences
Ltd., Seongnam 13488, Republic of Korea
| | - Sang-Won Lee
- Bioimaging
Team, Safety Measurement Institute, Korea
Research Institute of Standards and Science (KRISS), Daejeon 34113, Republic of Korea
| | - Jongman Yoo
- Department
of Microbiology, CHA University School of
Medicine, Seongnam 13488, Republic
of Korea
- Organoidsciences
Ltd., Seongnam 13488, Republic of Korea
| | - Min Beom Heo
- Nano-Safety
Team, Safety Measurement Institute, Korea
Research Institute of Standards and Science (KRISS), Daejeon 34113, Republic of Korea
| | - Tae Geol Lee
- Nano-Safety
Team, Safety Measurement Institute, Korea
Research Institute of Standards and Science (KRISS), Daejeon 34113, Republic of Korea
| |
Collapse
|